For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient relief with acute therapies, the greatest unmet need in migraine is for migraine prophylactic therapies with improved efficacy and tolerability than currently available therapies. Migraine prophylaxis was not the initial target of development for these therapies, resulting in drugs with sub-optimal efficacy, often only reducing migraine days by one or two days per month, and unfavorable side effects in a population that is generally otherwise healthy. Even in the highly genericized migraine prophylactic market, opportunity exists for branded therapies that offer greater efficacy and tolerability than currently available options.
Table of contents
- Migraine - Unmet Need - Detailed, Expanded Analysis Migraine Prophylaxis
Author(s): Angela Sparrow, Ph.D.
Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.
Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.